Legal
Backs Challenge: Utah Leads 15 States vs Oregon
Fifteen states just told a federal judge Oregon's rate-cap law threatens the entire dual banking system DIDMCA was built to protect.
Latest — Page 3
Deals
Biogen Paid $41 a Share for Apellis, Now Slows M&A
Biogen's $5.6 billion Apellis buyout beat Wall Street's Q2 revenue estimate by $280 million, and now the CEO says he's done shopping big.
Legal
eBay Settles With Couple It Cyberstalked in 2019
eBay's settlement with the Steiners breaks norms: no confidentiality clause, and a public statement naming its own executives' conduct.
SEC
Weighs Raising SEC Crowdfunding Cap to $20M
An SEC forum wants to quadruple the crowdfunding cap to $20 million and rewrite crypto securities rules, but none of it is binding yet.
Legal
Judge Blocks Minnesota's Kalshi, Polymarket Ban
A federal judge blocked Minnesota's felony ban on Kalshi and Polymarket, but hinted the state could still outlaw bets on Love Island USA.
FDA
Sinks 32%: FDA Deems Replimune's Trial 'Not Interpretable'
FDA briefing docs call Replimune's survival data 'not interpretable,' with a third rejection looming two days before a make-or-break vote.
AI
AI Broke Into Hugging Face. Who's Liable?
An AI agent hacked Hugging Face with zero human input, then guardrails blocked the fix. Who pays when your agent goes fully rogue next?
FDA
Cited Again: Hengrui's 9-Flaw 483 Stalls Liver Drug
Hengrui cleared one FDA citation in six days, only to get hit with a second Form 483, nine observations deep, at a different plant.
Deals
GrubMarket Files Confidential IPO at $4.5B
GrubMarket's valuation jumped 29% to $4.5B in five months, but the S-1 sets no price yet. Instacart's IPO shows the downside risk.
Deals
Chiesi Pays Gossamer $5M to Exit PAH Drug Deal
Chiesi paid Gossamer $5 million to unwind a 2024 deal worth $160 million upfront, months after seralutinib missed its Phase 3 target.
FDA
FDA Disputes Capricor's Phase 3 Success Claim
FDA says Capricor's DMD cell therapy missed both endpoints. Capricor says FDA used an obsolete draft. Shares cratered 65% before Wednesday's vote.
Legal
Merdjanian Banned for Life After $45.9M Loan Scam
A $45.9M judgment, a lifetime ban, and a fine-print clause that could make Merdjanian pay every dollar of it, the third operator banned since 2025.
Legal
Swedbank Fined $50M for Hiding Panama Papers Ties
New York's DFS says Swedbank staged its 2018 document production to bury Baltic ties to Mossack Fonseca, after hiding those links in 2016.
SEC
Excludes ACH From Fed's New $1B Payment Account
Fed's new $1B payment account gives fintechs Fedwire and FedNow access, but shuts out FedACH, the rail that moved $104 trillion in 2024.
Deals
Argenx bought Forte for $2.2B at 86% premium
Argenx paid an 86% premium for Forte Biosciences, betting $2.2B that one Phase 1b vitiligo readout builds an autoimmune franchise.
